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Advances in molecular engineering have led to customizable proteins for a multitude of clinical applications, 
leading to the rapid growth of the protein pharmaceutical market. Proteins can be advantageous compared to 
other treatment methods because of their functional complexities and high specificity that cannot be mimicked 
by small molecule drugs. Although there has been great interest and investment in advanced protein 
therapeutics, a majority of marketed proteins continue to have extracellular targets, despite the therapeutic 
relevance for intracellular protein therapies. Engineering efforts to improve cytosolic protein delivery often rely 
on modifying proteins through direct conjugation of polymers and peptides using reactive residues on amino 
acids. While this method has shown some success, the inability to modify a specific site within a protein can 
significantly hinder pharmacological action. Additionally, such approaches do not offer control over design 
variables that can be important determinants of targeting efficacy, such as ligand clustering. 
 
Previous work has demonstrated the ability to site-specifically insert biorthogonal reactive residues into proteins 
through unnatural amino acid incorporation, enabling direct protein conjugation with simple ‘click’ chemistries. 
Such an approach could be applied to protein therapeutics to explore the effect arrangement of delivery 
molecules has on protein bioactivity and intracellular delivery capabilities. In our work, we have demonstrated 
application of this approach for conjugation of epidermal growth factor receptor (EGFR) targeting peptides in 
fluorescent proteins.  By varying EGFR peptide arrangements we have demonstrated the ability to tune cellular 
internalization in inflammatory breast cancer (IBC) cells. Furthermore, this system has been adapted for delivery 
of a cancer suicide enzyme to enable IBC-targeted cell death through prodrug activation. Through this 
approach, we have identified the importance of ligand display for targeted protein delivery and applied these 
finding to enhance enzyme delivery to IBC cells. Future efforts will refine the efficacy of this method though 
incorporation of endosomal escaping peptides and hydrophilic polymers to address additional challenges 
associated with in vivo intracellular protein delivery.  
 
